The exact duplication of chromosomal DNA during each cell cycle ensures the correct inheritance of genetic material from mother to daughter cells. In eukaryotic cells, DNA replication can occur only when the origin of DNA replication is accurately marked by a group of proteins termed licensing proteins. One such protein is Cdt1, which is recruited first to the origin of DNA replication followed by cell division cycle 6 (Cdc6) and mini-chromosome maintenance proteins (Mcms). We previously reported that NIH3T3 cells overexpressing Cdt1 readily formed tumors in mice. To further investigate its oncogenic mechanism, we generated transgenic mice expressing Cdt1 in thymocytes. Our studies demonstrated that T-cell-directed Cdt1 transgenic mice showed normal T-cell development. However, such transgenic mice developed thymic lymphoblastic lymphoma when crossed with p53 null mice. Furthermore, tumor cells derived from NIH3T3 cells overexpressing Cdt1 displayed numerical and structural chromosomal aberrations in the form of ploidy, double minutes, translocation, inversion, chromosome end-to-end fusion and robertsonian mutation. Collectively, our studies suggest that Cdt1 overexpression most likely contributes to tumorigenecity by causing genomic instability.
Introduction
Cancer cells often display a growth advantage, which is acquired through multiple steps of genetic changes (reviewed in Hanahan and Weinberg, 2000) . For example, cells that acquire mutations in signal transduction pathways of external mitogenic stimulation may bypass growth factor requirements (Slamon et al., 1987; Yarden and Ullrich, 1988) . Mutations in proteins required for programmed cell death or angiogenesis could be advantageous for cells to survive or adapt to a new environment (Vaux et al., 1988; Bouck et al., 1996; Hanahan and Folkman, 1996; Bergers et al., 1999) . Moreover, mutations in cell cycle regulatory components may allow cells to divide continuously (reviewed in Hirama and Koeffler, 1995; Sherr, 1996) . Examples include overexpression of cyclinD1 in many cancers (Motokura et al., 1991) and inactivating mutations of INK4a in biliary tract and esophageal carcinomas as well as familial melanoma (Kamb et al., 1994; Nobori et al., 1994) . Additionally, inactivation of RB is necessary for retinoblastoma and adult small cell lung carcinoma development (Knudson, 1971; Friend et al., 1986; Hall and Peters, 1996) .
The eukaryotic cell cycle is a highly ordered process that results in faithful duplication of genetic information. Each cell cycle consists of the G1, S, and G2 phase followed by mitosis. Each transition is tightly controlled by many regulatory proteins to ensure that all DNA is replicated and divided equally between two daughter cells. Eukaryotic DNA replication is achieved by the coordinated firing of thousands of origins of replication sites throughout chromosomes. Recent studies have demonstrated that for DNA replication to occur, the origin of DNA replication sites must be specified in the late G1 phase. Six subunits of the origin recognition complex (Orc1-6; Bell and Stillman, 1992), Cdt1, Cdc-6 (Hartwell, 1976) , and Mcm proteins 2-7 (Moir et al., 1982; Maine et al., 1984) assemble sequentially onto an origin of replication in order for DNA replication to be initiated (reviewed in Fujita, 1999; Quintana and Dutta, 1999; Saxena and Dutta, 2003; Shreeram and Blow, 2003) . The state of DNA loaded with these proteins is called 'licensed'. At the G1/S transition, cyclin-dependent kinases are activated and DNA replication is initiated.
Cdt1 was originally isolated in fission yeast as a target of the Cdc10 transcription factor (Hofmann and Beach, 1994) . It is required for DNA replication and inhibition of mitosis. Recent studies have demonstrated that Cdt1 performs a critical function in the DNA replication licensing process (Blow and Tada, 2000; Maiorano et al., 2000; Nishitani et al., 2000) . In fission yeast, Cdt1 cooperates with Cdc18 (Cdc6 in eukaryotes) to promote initiation of DNA replication. Cdt1 and Cdc18 can be co-precipitated from fission yeast extracts using antibodies against either. Thus, it appears that both Cdt1 and Cdc6 bind together to Orcs, where they are required for licensing. In vitro DNA replication studies using Xenopus egg extracts demonstrated that Xenopus Cdt1 (XCdt1) is required to initiate DNA replication. XCdt1 binds Orc independently of Cdc6, before Mcms, and is destabilized from chromatin upon initiation of DNA synthesis. Drosophila double-parked (Dup) gene, which is essential for the initiation of DNA replication, has a strong sequence homology to Cdt1 (Whittaker et al., 2000) . Dup colocalizes with Orc2, a component of the replication machinery. The dup mutants are also defective in DNA replication, both in embryogenesis and in oogenesis (Whittaker et al., 2000) . Together, these studies strongly suggest that Cdt1 is essential for the initiation of DNA replication.
We previously isolated Cdt1 by retroviral insertional mutagenesis and reported that Cdt1 was overexpressed in many human cancer cell lines. Moreover, NIH3T3 cells overexpressing Cdt1 readily formed tumors in mice (Arentson et al., 2002) . To further establish the causal relationship between Cdt1 overexpression and oncogenecity, we generated transgenic mice expressing Cdt1 under the T-cell-specific Lck proximal-promoter (Lck pr ; Wildin et al., 1991) . We report here that Cdt1 overexpression under the Lck pr promoter was not sufficient for T cells to acquire growth advantage, but that T-cellspecific Cdt1 overexpression in the absence of p53 resulted in lymphoblastic lymphoma. Furthermore, a tumor line derived from NIH3T3 cells overepxressing Cdt1 contained numerous chromosomal abnormalities. We propose that an abnormal expression of Cdt1 can cause genomic instability and tumor formation in vivo.
Results

Lck
pr -Cdt1 transgenic mice show normal T-cell development, but some develop mesenteric node hyperplasia in old age
To better assess the effect of Cdt1 overexpression in vivo, we generated transgenic mice expressing Cdt1 under the proximal promoter of Lck. Two independent lines were generated and characterized. Initially, cellularity and T-cell development of transgenic thymi were examined and evaluated. Cdt1 transgenic thymi, in general, showed similar cell number and T-cell development compared to their nontransgenic littermates. Moreover, Cdt1 transgenic thymocytes did not contain a higher percentage of dividing cells, as analysed by in vivo BrdU labeling (not shown). In addition, T cells present in the spleen did not show a greater cell proliferation, as analysed by [ 3 H]thymidine incorporation (not shown). While these studies suggested that cells overexpressing Cdt1 did not show any abnormality, we detected hyperplasia in some of the mesenteric node of older transgenic mice (>20 months of age). Specifically, in four mice we observed massive mesenteric adenopathy (Figure 1a and b) , including 1 case of frank lymphoma (Figure 1c ). In two of the nonmalignant adenopathies, the normal nodal architecture was altered by a mixed proliferation of small lymphocytes, immunoblasts and plasma cells especially in the marginal sinuses (Figure 1a) . In a third nonmalignant adenopathy, nodal architecture was largely obliterated by a histiocyte-rich process including multinucleated giant cells (Figure 1b ). Both these histologies are nonspecific and do not strongly suggest any particular infectious or autoimmune etiology. One lymphoma had features most consistent with diffuse large-cell lymphoma. It was easily distinguished from lymphoblastic lymphomas by its rounded nuclear contours and relatively abundant cytoplasm (compare Figure 1c and f) .
Recent studies suggested that DNA rereplication initiated by Cdt1 overexpression was recognized as a DNA-damage signal and activated the p53-mediated checkpoint pathway (Vaziri et al., 2003) . It was expected then that the effect of Cdt1 overexpression would be readily revealed in the absence of p53. Thus, we determined if p53 could modulate Cdt1-mediated oncogenic potential. To this end, we generated Lck pr -Cdt1;p53 À/À mice by crossing Lck pr -Cdt1 to p53 À/À mice. As reported, the majority of p53-deficient mice died by the time they reached 10 months of age ( Figure 2 and Table 1 ). In all, 10 neoplasms were detected in seven of nine p53 À/À mice at necropsy. The neoplasms included: two lymphoblastic lymphomas primarily involving the thymus, five large-cell or other nonHodgkin's lymphomas more substantially involving the spleen and nonhematopoietic tissues and also the thymus, one subcutaneous sarcoma, one angiosarcoma and one poorly differentiated nonhematopoietic neoplasm metastatic to the heart. One p53 À/À mouse (2434) had no histopathologic abnormalities (160 days). One mouse (1707) showed massive hepatosplenomegaly secondary to extramedullary hematopoiesis with abundant hemophagocytosis and a necrotic thymus but no tumor was seen. In summary, only two out of nine p53 À/À mice developed thymic lymphoblastic lymphoma (Figure 1d ), while five developed lymphomas with histologies more consistent with non-Hodgkin's B-cell lymphomas.
All Lck pr -Cdt1;p53 À/À mice analysed succumbed to tumors and died by 5.5 months (Figure 2) . Overall, Lck pr -Cdt1;p53 À/À mice had grossly enlarged thymi compared to their p53 À/À littermate controls (14 out of 19, Figure 3 and Table 1 ). Importantly, all 19 thymi had histologic features consistent with lymphoblastic lymphoma, a high-grade non-Hodgkin's lymphoma characterized by abundant mitoses, apoptotic bodies and necrosis (Figure 1d -f, not shown). Of the 19, 11 had varying degrees of splenomegaly (range 0.12-1.2 g, wildtype controls 0.09-0.15 g) and were characterized by lymphoblastic lymphoma (Figure 4 ). The lymphoma was confined largely to the peri-arteriolar lymphatic sheath (the physiologic T-cell-rich zone) with preservation of the primary follicles (the physiologic B-cell-rich zone, Figure 4 ). Collectively, these data demonstrate that 100% of animals develop thymic lymphoblastic lymphoma when Cdt1 is overexpressed in T cells in a p53 null background.
We examined T-cell development of 17 p53 À/À mice that developed tumors as well as those that were sacrificed as littermate controls (Table 1) . Typically, T-cell development in the thymus can be monitored by CD4 and CD8 expression. CD4 and CD8 doublepositive T cells first develop from double-negative T cells. Double-positive T cells then downregulate either CD4 or CD8 to generate CD8 or CD4 singlepositive T cells, respectively. When examined by flowcytometry, CD4 and CD8 double-positive T cells represent B80% of the total thymocytes, while CD4 or CD8 single-positive T cells represent 5-10% of the total thymocytes ( Figure 5a and b, 3009 and 2660). As shown in Figure 5a , p53 À/À mice including those that were used as littermate control (not shown) showed a wide range of abnormal T-cell development. For example, some showed an arrest at CD4 and CD8 double-positive stage, some were arrested at double-negative stage, and some showed an expansion of single-positive CD4 or CD8 T cells. Two mice that developed thymic lymphoblastic lymphoma (2472 and 2475) arrested at doublepositive and CD8 single-positive stage, respectively. Only two (2681 and 1945) out of 17 mice showed relatively normal T-cell development (not shown). 
Tumors derived from Cdt1 overexpression show genomic instability
Histologic examination of Lck pr -Cdt1;p53 À/À thymic lymphoblastic lymphoma (LBL) samples showed multiple mitotic figures, suggesting that most tumor cells were highly proliferative. The 'starry sky' appearance prominent in Figure 6a is a classic feature of tumors with both high mitotic and apoptotic rates, as is typical of human LBL. LBL is also almost uniquely characterized among lymphomas as having a fraction of cells positive for Ki67 of >99% and being poised to undergo apoptosis. While apoptotic forms were common, only a small portion of tumor sections showed zonal necrosis. To confirm that they were truly proliferating, we performed Ki67 staining and TUNEL assays on Lck To better understand the Cdt1 oncogenic mechanism, we first examined the status of several proteins that are critical for cell cycle regulation. Wild-type thymocytes had a basal level of Cdt1 expression (Figure 7) , which is consistent with previous studies that thymus and bone marrow expressed Cdt1 (Arentson et al., 2002 Table 1 Cdt1 and cancer J Seo et al thymic lymphoblastic lymphoma samples that were examined showed an upregulation of Cdt1 expression (Figure 7 and data not shown). This confirmed that Cdt1 upregulation indeed correlated with tumorigenecity. The expression levels of Geminin, a known inhibitor of Cdt1 (Wohlschlegel et al., 2000; Tada et al., 2001) , was higher in all Lck pr -Cdt1;p53 À/À tumor samples compared to wild-type or p53 À/À thymus. Importantly, Geminin was also expressed at high levels in p53 À/À -derived tumor (2472), suggesting that overexpression of Geminin is independent of Cdt1 overexpression. In contrast, p27 expression was dramatically decreased in all tumors, while its expression was normal in wild-type or p53 À/À thymus. thymocytes. However, we could not obtain enough metaphase cells from Lck pr -Cdt1 single transgenic thymocytes to further examine the possibility that Cdt1 can cause genomic instability. Therefore, we performed chromosome analyses on NIH3T3 cells overexpressing Cdt1 and tumor-derived line from NIH3T3 cells overexpressing Cdt1 (Arentson et al., 2002) . As shown, tumor-derived cells contained numerous chromosomal abnormalities, including chromosome end-to-end associations, chromosome gaps and breaks, and chromatid gaps and breaks at metaphase, and ploidy ( Figure 9 and Table 2 ).
Discussion
Many studies indicate that proteins involved in cell cycle regulation need to be tightly regulated and that abnormal expression of these proteins could result in cancer. Even though these studies point to the importance of proteins involved in cell cycle regulation, few studies have examined the relationship between deregulation of DNA replication and the development of cancer. We studied transgenic mice to determine whether a protein involved in licensing of DNA replication plays a functional role in tumorigenecity. Present studies demonstrate that transgenic mice expressing Cdt1 specifically in T cells showed no significant phenotype. However, such transgenic animals all developed lymphoblastic lymphoma in the absence of p53. The p53 check point and Geminin have been implicated in regulating Cdt1 activity to ensure that DNA rereplication does not occur in a given cell cycle. For example, previous studies demonstrated that rereplication induced by Cdt1 overexpression activated ATM/ATR and Chk2 kinases, which then induced p21.
This suggested that rereplication mediated by Cdt1 overexpression was recognized as a DNA damage signal and activated the ATM/ATR/Chk2 DNA damage checkpoint pathway (Vaziri et al., 2003) . Thus, genetic stability of a given cell can be maintained in part by a p53-dependent checkpoint pathway by inhibiting DNA rereplication in a given cell cycle. Our transgenic studies further support the notion that the p53 checkpoint mechanism is critical for inhibiting Cdt1-mediated rereplication. This in turn suggests that the oncogenic potential of Cdt1 overexpression can be observed only in the absence of p53 in vivo. As for Geminin, many studies indicate that Geminin binds directly to Cdt1, and inhibit reloading of Cdt1 onto the origin of DNA replication (Wohlschlegel et al., 2000; Tada et al., 2001) . This prompted many investigators to speculate that Geminin could function as a tumor suppressor. Indeed, several studies demonstrated that inhibition of Geminin expression resulted in rereplication even in the presence of functional p53 (Melixetian et al., 2004; Zhu et al., 2004) . Recent studies, however, showed that cancer cells expressed high levels of Geminin (Wohlschlegel et al., 2002; Wharton et al., 2004; Xouri et al., 2004) . Consistent with this, we also found that Geminin was expressed at higher levels in tumors derived from p53 À/À as well as Lck pr -Cdt1;p53 À/À mice. Further studies are required to clarify Geminin function in DNA rereplication and cancer development.
The mechanism by which Cdt1 overexpression enhances tumorigenecity in p53 À/À mice is not clear. As the S-phase frequency among Lck pr -Cdt1;p53 À/À thymic lymphoblastic lymphoma and p53 À/À tumor samples was similar, Cdt1 overexpression, even in the absence of p53, does not appear to confer a growth advantage. A more intriguing idea is that Cdt1 overexpression causes genomic instability. First, chromosomal analyses on thymocytes from Lck pr -Cdt1;p53 À/À and p53 À/À mice indicated that Lck pr -Cdt1;p53
À/À cells in metaphase showed multiple chromosomal abnormalities. Second, a tumor-derived cell line from NIH3T3 cells overexpressing Cdt1 contained numerous chromosomal abnormalities, including chromosome end-to-end associations, gaps and breaks, and chromatid gaps and breaks at metaphase as well as ploidy. Although these studies do not directly prove that Cdt1 overexpression leads to genomic instability, it is conceivable that Cdt1 deregulation contributes to genomic instability especially when the p53 check point pathway is abrogated.
Considering that cancer cells are characterized by their extensive proliferation, marker proteins specific to propagating cells could be useful for early detection of cancer. Typically, expression of Ki67, PCNA, cyclins, cell cycle duration and mitotic figures are used to assess the rate of proliferation. As licensing proteins are required for DNA replication, there could be a direct correlation between the expression of licensing proteins and cell proliferation (reviewed in Shreeram and Blow, 2003) . For example, Mcm2 has been shown to be a good marker for detecting premalignant lesions of the lung (Tan et al., 2001) . Additionally, Cdc6 expression was detected in high-grade cervical squamous and glandular dysplasia (Bonds et al., 2002) and carcinoma as well as in brain tumors (Ohta et al., 2001) . Our current studies support the basic model that the expression of licensing proteins can indeed serve as indicators of proliferation. It should be emphasized that the effect of Cdt1 overexpression is pronounced in the absence of functional p53. As more than 50% of human tumors have mutations in p53 (reviewed in Greenblatt et al., 1994; Donehower, 1996) , we propose that Cdt1 expression in the context of p53 could lead to a better assessment or early detection of premalignant lesions. Future studies are required to verify this notion.
Materials and methods
Mice
The Lck pr -Cdt1 transgenic construct was generated by inserting a 2. 2-kb fragment containing the mouse Cdt1 cDNA into the p1017 vector. The p1017 vector contains the human growth hormone enhancer and the Lck proximal promoter for T-cell-specific expression (Chaffin et al., 1990) . Lck À/À mice. To distinguish between the wild-type and knockout p53 alleles, the following two sets of primers were used, two forward primers Chromosome end-to-end associations, chromosome gaps+breaks and chromatid gaps+breaks at metaphase, and bridges at anaphase were compared in three isogenic cell types. (*) indicates that the differences are significant as assessed by wfrom the exon 5 of wild-type p53 (5 0 -CCT CAA TAA GCT ATT CTG-3 0 and 5 0 -ATA CAA ATT TCC TTC CAC-3 0 ) and two reverse primers from the neomycin gene (5 0 -AGG CTA TTC GGC TAT GAC TG-3 0 and 5 0 -GGA CAG GTC GGT CTT GAC A-3 0 ).
Flow cytometry
Single-cell suspension was prepared from the thymus, spleen, and bone marrow by dispersing the organs between two glass slides and then passing through mesh filters. Cells were treated with hypotonic lysis buffer (0.15 M NH 4 Cl, 1 mM KHCO 3 , and 0.1 mM Na 2 EDTA) to remove red blood cells. Cells were then stained with following conjugated antibodies: anti-CD4-FITC, anti-CD8a (Ly-2)-PE from Pharmingen. Flow cytometry was performed on either a Becton Dickinson FACScan or FACScaliber, and FACS data were analysed with CellQuest software (Becton-Dickinson).
Histological analysis
Mouse tissues were fixed in 10% buffered formalin for 24 h and embedded in paraffin. A histopathological diagnosis was made from a hematoxylin and eosin (H&E)-stained section. For immunohistochemical analysis, tissue sections were stained with anti-Ki-67 (Dako) followed by anti-rat biotinylated IgG and Strepavidin-HRP. For detection of apoptosis, TUNEL staining was performed using the In Situ Cell Death Detection Kit, POD (Roche), following the manufacturer's instructions.
Western blot analysis
Mouse thymus tissues were homogenized in radioimmunoprecipitation (RIPA) buffer containing 50 mmol/l Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and 50 Â complete proteinase inhibitor cocktail (Boehringer Mannheim). Tissue and cell debris were removed by centrifugation and protein concentration was determined by Bio-Rad protein assay kit. The protein extracts, 100 mg, were mixed with 3 Â SDS loading buffer (125 mmol/l Tris buffer, pH 6.8, 20% glycerol, 2% SDS, 2% b-mercaptoethanol and 1 mg/ml bromophenol blue) and electrophoresed in 8-12% SDS-polyacrylamide gel under reducing conditions and transferred to a nitrocellulose membrane (Schleicher and Schuell). The membrane was incubated 1 h in blocking buffer (TBS with 5% nonfat dry milk) and then incubated overnight at 41C with the following primary antibodies: rabbit anti-human p27 (C-19), goat antimouse Actin (I-19), rabbit anti-human Chk2 (H-300) and goat anti-mouse Geminin (M-16) from Santa Cruz Biotechnology, rabbit anti-mouse p19/ARF, and hamster anti-mouse Cdt1.
The signals were visualized with the chemiluminescence ECL detection system (Amersham).
Cell ploidy analysis from paraffin-embedded tissues
Formalin-fixed, paraffin-embedded thymus tissue sections were used for ploidy analysis. Sections were deparaffinized, rehydrated in an ethanol/water series, and digested with 0.5% pepsin (pH 1.5, in normal saline) for 60 min in a water bath at 371C. The digested tissues were filtered through a 40-mm nylon mesh, washed in HBSS, resuspended in HBSS with 0.1 mg of RNase and 0.1% of Triton X-100, and incubated for 20 min at 371C. After pelleting, cells were resuspended in 1 ml of propidium iodide (PI) solution (50 mg/ml PI in HBSS) and analysed with a Becton-Dickinson FACSCaliber.
Genomic instability assay
Chromosomal instability was examined at metaphases and anaphases from exponentially growing cells, which were prepared by a standard procedure . Giemsa-stained chromosomes of metaphases and anaphases were analysed for chromosome aberrations. Detection of telomeres on metaphase chromosomes was obtained by FISH with a telomere sequence-specific PNA probe (Hunt et al., 2004) .
